PRESIDENT and CEO for CPR STRATEGIC MARKETING AND COMMUNICATIONS

Joseph Carabello has been involved in a broad range of developmental and operational activities relating to marketing communications throughout his career spanning healthcare, managed care, hospital marketing, medical travel, e-business and technology sectors. Holding key positions in several managed care organizations, as well as venture-based startups and consulting firms, Mr. Carabello has extensive experience in the healthcare industry. He has served on the board of numerous companies including managed care organizations, physician partnerships, and public service organizations.

In addition, Mr. Carabello has acted as a consultant to the Office of Health Maintenance Organizations of the U.S. Department of Health and Human Services on marketing HMOs. He has served on the Board of Health Systems Agencies (HSAs) in New Jersey and Louisiana. A US Army Veteran, Carabello has served on several corporate and community boards, including Alvin Healthcare, Unotron LTD, Sphera Global Healthcare, The Bergen Community College Foundation, and The Molly Foundation for Juvenile Diabetes. Mr. Carabello recently initiated and funded Hannah’s Kitchen, a free food pantry for the underserved, located at a FQHC in a Northeast food desert.

CHIEF CREATIVE OFFICER for CPR STRATEGIC MARKETING AND COMMUNICATIONS

Laura Carabello, founder and principal owner of CPR Strategic Marketing and Communications, has worked with over 1,000 companies, including public and private organizations, as a strategic consultant. She has been instrumental in the growth and development of multiple organizations both domestic and worldwide. She currently serves on the International Committee of the Self Insurance Institute of America and serves as special advisor to the American Macular Degeneration Foundation.

Recognized for innovation, Laura was on the founding team of Teladoc, the world’s leading telemedicine company. She has been invited by the US Federal Trade Commission to testify on healthcare advertising and marketing ethics and was recently tapped to develop special projects for Forbes magazine. She is the publisher and managing editor of Medical Travel and Digital Health News, the authoritative, online business-to business international newsletter of the medical tourism industry covering US domestic and international medical travel.

ASSISTANT PROFESSOR, DEPARTMENT OF DERMATOLOGY at the UNIVERSITY OF MINNESOTA

Dr. Marna E. Ericson currently serves as Assistant Professor, Department of Dermatology at the University of Minnesota. Dr. Ericson joined the University of Minnesota Department of Dermatology in 1996 as part of the Clinical Research Division team. She is Director of the research laboratory in Dermatology located in Diehl Hall and leads the Basic Science Friday resident lecture series.

Over the past 15 years, Dr. Ericson has adapted advanced imaging methodologies with new molecular techniques to improve understanding of vector-borne diseases with a long-term goal of deciphering the mechanisms and complex nature of co-infections. Her interests lie in imaging with special emphasis on single- and multi-photon laser scanning confocal microscopy. Her expertise in imaging has led to fruitful collaborations with other investigators outside the Department of Dermatology in the fields of infectious diseases, oncology, neuroscience, rheumatology, engineering, dentistry, and orthopedics.

Dr. Ericson has successfully administered collaborative projects with peer-reviewed publications as well as funding. With Innovation as a hallmark of her research endeavors, Professor Ericson has contributions like understanding and treating Cancer pain, identifying molecular targets of phytochemicals, comprehending the role of the peripheral nervous system in skin and hair biology, and recognizing the implications of Bartonellosis.

Dr. Ericson’s current research activities include cancer pain in a murine model, mechanisms of hair growth, tumor/T-cell interactions, mechanism of mammalian/tick infection, and second harmonic imaging of collagen.

Dr. Ericson became a Fellow of the Thought Leadership & Innovation Foundation (TLI) in 2018. She has contributed to Science with 47 peer-reviewed papers and has received several honors and awards in Imaging Science, including in 2013 as a Finalist in Posters/Graphics for the National Science Foundation (NSF) Science Engineering Visualization Challenge.

FOUNDER AND CHIEF MEDICAL OFFICER for MEDIORBIS

Dr. Jonathan Wiesen is a pulmonary and critical care physician, teacher, researcher and medical technology pioneer with a passion for clinical medicine and telehealth innovation.

Graduating from the Albert Einstein College of Medicine with distinction in research, he completed his training in internal medicine as well as pulmonary and critical care at the Cleveland Clinic - earning an advanced teaching degree and several teaching and research awards.

As founder and chief medical officer of MediOrbis, he leads the development of ground-breaking clinical programs for monitoring and managing chronic medical conditions and providing integrated medical specialty services. He has also developed a global network of top physicians to deliver the company’s telemedicine services worldwide.

Currently, Dr. Wiesen is a pulmonary specialist at Ben Gurion University’s Soroka Medical Center, where he directs the Cardio-Pulmonary Exercise Program. He plays an active role as an advisor to a number of medical technology companies, and serves on the board of several companies including the most active venture capital firm in Israel, specializing in clinical assessment and due diligence.

FOUNDER AND EXECUTIVE DIRECTOR of the TRANSLATIONAL MEDICINE GROUP

Dr. B. Robert Mozayeni is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently.

Dr. Mozayeni is a Rheumatologist with graduate and post-graduate physician-scientist training from Albany Medical College, Yale University, Howard Hughes Medical Institute, and the National Institutes of Health (NCI, NHLBI, and NIAMS). He is presently in private practice in Bethesda, MD where he specializes in chronic inflammatory diseases having rheumatic and neurovascular manifestations.

Dr. Mozayeni is the founder and Executive Director of the Translational Medicine Group where he has developed and commercialized software that supports data-driven methods to accelerate the evaluation and improvement of patient-centered care pathways. Under an ongoing research collaboration, Dr. Mozayeni maintains an observational clinical evaluation of the significance of Bartonella infection in a cohort of several hundred human patients with otherwise unexplained chronic conditions. Clinical correlations between Bartonella species and various conditions are being determined as part of ongoing research which continues to redefine diagnostic and therapeutic options as dictated by clinical experience.

CHIEF EXECUIVE OFFICER of HEALYTICS

Peter serves as Chief Executive Officer of Healytics, a genetic data management platform and COO/EVP of CRE Technologies, leading the development of cyber solutions and products for the healthcare landscape. Pete has more than thirty-five years of experience in developing very complex technology solutions, across a wide spectrum of verticals including healthcare, media, manufacturing and cyber. He founded and led Performance Technology Group, an infrastructure engineering and outsourcing service provider focusing on the healthcare and intel markets. PTG, Inc. was sold to World Wide Technology in 2009 winning the prestigious Association of Corporate Growth’s Deal of the Year Award.

Previously, Pete was a Senior Staff member at Johns Hopkins Bloomberg School of Public Health where he supported a variety of research studies including Migraine Headache, Prospective study of Central Nervous System Function in Amateur Boxers and the Human Genome.

FOUNDER and CEO at GENEGINI

Dr. Day joins TLI from the United Kingdom, expanding the Foundation’s global presence. His interests lie primarily in quantitative measurement, and he is driven to improve the quality of big, deep medical data by bringing engineering to the molecular sciences. His expertise in in nucleic acid measurement tools for quantitative integrative analyses of bio analytes, pathway function and mechanism analyses, microbiome and chronic inflammatory diseases, miniaturization for single cell studies and role of biological heterogeneity, systems biology and synthetic biology applications.

Dr. Day is the Principal Investigator in Synthetic Biology & Quantitative Genomics, Faculty of Biology, Medicine and Health Sciences, University of Manchester and Manchester Institute of Biotechnology (2007 to Present); Honorary Professor, Department of Medicine, University of Cape Town, South Africa (2021 to present); Honorary Professor, Bioengineering, Electrical Engineering & Computer Science, and Biophysics, UC Berkeley (2019 to present) and was Honorary Professor, Department of Biomedical Engineering, UC Irvine (2013 to 2018).

CHIEF EXECUTIVE OFFICER of ACQUIRED IMMUNE MEDICINES, INC

Dr. Robin Robinson serves concurrently as a Fellow for Regenerative Medicine and Chronic Diseases at TLI, the acting Chief Executive Officer of Acquired Immune Medicines, Inc. developing new vaccines for influenza and other emerging pathogens, and an independent senior executive consultant for many pharmaceutical and biotechnology companies in the U.S. and Europe. He leads TLI’s development of cellular therapies to treat wounds from thermal, radiation, and diabetic wounds to establish a new regenerative medicine program.

He reentered the private pharmaceutical industry sector after retiring in 2016 from federal public service at the U.S. Department of Health and Human Services, where he served from 2008 - 2016 as the first director of the Biomedical Advanced Research and Development Authority (BARDA) and Deputy Assistant Secretary for Preparedness and Response. Dr. Robinson brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of drugs, vaccines, diagnostics, and medical devices for man-made threats, pandemic influenza, and emerging infectious diseases. 38 of these medical countermeasure products supported by BARDA supported under his leadership were FDA approved. Under his leadership, BARDA established premier programs that developed treatments for acute radiation syndromes (ARS) with industry partners; novel cellular therapy technologies were utilized to treat ARS-associated neutropenia and thermal and radiation burns. In 2018, Dr. Robinson was recognized as one of top 100 innovators in medicine.

While at BARDA, Dr. Robinson served from 2004-2008 as the Director for the Influenza & Emerging Disease Division. Dr. Robinson established a program with scientific and technical experts to implement the national and global strategic plans and policies for the development of new influenza antiviral drugs, vaccines, and diagnostics outlined in the National Strategy for Pandemic Influenza. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense’s Clay Dalrymple Award in 2008, the HHS Distinguished Service Award three times, and a finalist for the Service to America Medal in 2009. From 2013- 2015, Dr. Robinson was recognized as one of the top 50 most influential persons worldwide in vaccines by Vaccine Nation.

Prior to public service, Dr. Robinson served as the Director of Vaccines at Novavax, Inc. (Rockville, MD) from 1995-2004, where he led the development of 20+ vaccines to hepatitis B and E, influenza, noroviruses, and human papilloma viruses from early development, clinical trials, manufacturing scale-up, and commercialization through FDA licensure. He developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers. Dr. Robinson pursued research from 1983-1992 on the molecular pathogenesis of herpesviruses and HIV while on faculty in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School.

Dr. Robinson received a Bachelor of Science degree from Millsaps College and a doctoral degree from the University of Mississippi Medical School in microbiology. He completed a NIH postdoctoral fellowship with the State University of New York at Stony Brook in molecular oncology.

Dr. Robinson also serves on the Senior Advisory Group for the World Health Organization (WHO) on emerging infectious diseases and pandemic influenza. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.

ROSSIGNOL MEDICAL CENTER

Dr. Rossignol, MD FAAFP is a board-certified family physician. He received his Doctorate of Medicine at the Medical College of Virginia and completed his residency in family medicine at the University of Virginia. Coming from an academic background, Dr. Rossignol searched the medical literature looking for a solution after both of his children were diagnosed with autism. He has made it his mission to research and publish in autism. Since 2006, he has 55 papers, abstracts, editorials, and book chapters (including those in press) concerning autism and related conditions. Dr. Rossignol has a special interest in autism spectrum disorders, PANS/PANDAS, cerebral palsy, and related neurological and developmental disorders as well as medically complex children and adults. Dr. Rossignol is a Fellow of the American Academy of Family Physicians (FAAFP) and a Fellow of the Medical Academy of Pediatric Special Needs (FMAPS). Dr. Rossignol sees patients in all three offices in California and Florida.

FOUNDER of disABLED LIFE ALLIANCE

Paul Kent is the Founder of disAbled Life Alliance, a public benefit corporation dedicated to bringing about meaningful change within the disabled community. He embarked on this mission on December 1st, 2020, by undergoing a groundbreaking bilateral below-the-knee amputation procedure known as the Ewing Amputation. In becoming the first bilateral "non-traumatic" patient to participate in Dr. Matthew Carty's clinical surgical study at Brigham and Women's Hospital, Paul successfully put an end to a decade-long, life-threatening health crisis.

Before his involvement in disability advocacy, Paul spent a significant portion of his professional career in the financial services industry. He held various senior positions at Jefferies and Company, ultimately overseeing US Equity Sales and Trading. Following his retirement from Jefferies, Paul provided guidance to smaller investment banks on various matters and launched Idlewood Capital Partners, a firm dedicated to supporting first-time fund managers. During this time, he cultivated relationships with

ultra-high-net-worth individuals and family offices, which ultimately led him to become involved in the social impact movement. In 2018, Paul merged his capital markets business with a philanthropic advisory firm. Through this collaboration, he developed a new business model that not only advised family offices and foundations on gifting, granting, and impact investment activities but also formulated and executed a comprehensive plan to achieve the desired social impact.

Drawing from both his professional expertise and personal experiences, Paul has created an innovative model that will focus exclusively on addressing the challenges faced by the disabled community.

Paul is relishing the opportunities that his renewed lease on life has presented to him. He considers his Ewing Amputation to be a precious "gift" that has enabled him to pursue an active, healthy, and adventurous lifestyle that eluded him for over a decade. After the ten-year hiatus and post-amputation, he has resumed many of these pursuits, including running the past two Boston Marathons, where he raised a substantial amount of funds for the Stepping Strong Center for Trauma Innovation and the Spaulding Rehabilitation Hospital President's Fund.

Paul is the proud father of two sons, Robert and Peter, who are the inspiration behind his quest to Facilitate Meaningful Change! His oldest son Robert, a USN Officer resides in Bremerton Washington. Paul’s younger son Peter is a thriving technology entrepreneur living and working in New York.

DIRECTOR OF GRANTS, PARTNERSHIPS, ADVOCACY for the AMERICAN MACULAR DEGENERATION FOUNDATION

Matthew Levine has been a communications professional for 30 years, with a vision research focus since 2003. At the American Macular Degeneration Foundation (AMDF), his portfolio includes the expansion of the AMDF grant program, the development of strategic partnerships, advocacy engagement, and the creation of educational content. He also is a painter, concentrating in watercolor. He graduated from Oberlin College with a dual major in Creative Writing and English, and received a Master of Fine Arts degree (in Creative Writing) from Columbia University.

EXECUTIVE DIRECTOR, EPIDEMIC ANSWERS

BETH LAMBERT is a former healthcare consultant and teacher. As a consultant, she worked with pharmaceutical, medical device, diagnostic and other health care companies to evaluate industry trends. She is the author of A Compromised Generation: The Epidemic of Chronic Illness in America’s Children (Sentient Publications, 2010). She is also a co-author of Epidemic Answers’ Brain Under Attack: A Resource for Parents and Caregivers of Children with PANS, PANDAS, and Autoimmune Encephalitis. In 2009, Beth founded Epidemic Answers and currently serves as Executive Director. Beth attended Oxford University and graduated from Williams College and holds a Masters Degree in American Studies from Fairfield University. She is a member of Alpha Sigma Nu, the Jesuit Honor Society. Beth is also the mother of three young children.

BRANDT VENTURES, CEO

JEFFREY BRANDT founded the award-winning Ability Prosthetics and Orthotics, an evidence-based P&O practice with fourteen offices across three states. Since its inception in 2004, Ability has led the advancement and implementation of outcome measures in daily practice, prioritizing a focus on patient care delivery, business analytics, community based adaptive programs and comparative effectiveness product research and development. Brandt also established Lifenhanced magazine and is a co-founder of Kinetic Revolutions of which the most notable product is the height-adjustable pylon for use on prosthetic limbs. Ability was acquired in 2020 by global leader, Ottobock Healthcare, where Brandt served as the VP of Clinical Operations and the Director of Business Development for Ottobock.Care until 2022.

After graduating from Penn State University, Brandt completed the prosthetics technician program at Spokane Falls Community College and then attended the Northwestern University Feinberg School of Medicine’s Prosthetic & Orthotic programs. He completed orthotic and prosthetic residencies at the Rehabilitation Institute of Chicago and Lawall P&O, servicing A.I. DuPont Children’s Hospital, respectively. As a student, Brandt was awarded the Gunther Gehl Prosthetics Scholarship by the Midwest Chapter of the American Academy of Orthotists and Prosthetists (AAOP) and has been named to the O&P News 175, is a ROMP Empowerment Through Mobility Award winner and most recently, received the AAOP’s 2022 Distinguished Practitioner Award.

Brandt has served as a board member (and past treasurer) for the American Orthotic & Prosthetic Association (AOPA), is an advisory board member of two O&P master’s programs, as well as an advisor & investor in multiple early-stage healthcare ventures. He recently published a manuscript in the Canadian Prosthetics & Orthotics Journal on the Changing Operational Perspectives in the Prosthetics & Orthotics Profession and planning a follow-on manuscript detailing his current efforts as a member of the Limb Loss & Preservation Registry’s External Collaborative Panel (ECP), focused on operationalizing the registry.

BIOTECH COMMERCIAL EXECUTIVE, INDEPENDENT CONSULTANT, and STRATEGIC ADVISOR

DAN BELTRANI is a successful commercial leader with a proven track record of surpassing revenue and profit targets in the biotech and pharmaceutical industries. He has a deep passion for leading and inspiring teams and building businesses that deliver on a mission to improve lives and better serve patients and the health care professionals who care for them. Dan has demonstrated success in a range of activities: talent management, strategic business planning, new product development, product launches, portfolio management, orphan disease, third party alliances, limited distribution networks, and national genetic screening programs.

Currently, Dan is supporting AscellaHealth, in acquisitions and mergers. AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offering a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies.

Prior to his engagement at AscellaHealth, Dan was Vice President, Head of US BioPharma Marketing at Grifols for over 10 years. He built and led a team of HCP and consumer marketing professionals responsible for developing strategic plans and aligned tactical execution for US BioPharma rare disease business. Diverse portfolio spans allergy, immunology, neurology, pulmonology, hematology, and specialty categories. Total revenues exceeded $3B.

Mr. Dea Belazi leads AscellaHealth, which provides pharmacy benefit manager services to nearly 3 million people in the commercial, Medicaid and Medicare markets.

He operates the independent consultancy, AlchemiPharma, whose clients include pharmaceutical manufacturers and health plans. The consultancy focuses on many areas including pharmacy benefit strategies, formulary management, contracting, business development strategies, and health economics and outcomes research. Belazi is also the principal and owner of CrowdHealth, a social networking site for consumers to share healthcare experiences. Belazi founded and leads the business development of two other Pharmacy Benefit Managers, PerformRx and FutureScripts, which was acquired in September 2010 by Catamaran. Mr. Belazi holds a Masters of Public Health at Johns Hopkins University.

Dr. Charles Bruce Green was the 20th Air Force Surgeon General and the functional manager of the U.S. Air Force Medical Service.

He is an expert in anything related to the Military Health System, veterans’ health, medical disaster response, air evacuation, patient centered medical home, connected health, and health analytics. Dr. Green is a managing director with Deloitte Consulting LLP, serving as chief medical officer for Deloitte’s Federal Health practice.

Dr. Green is an advisor to Deloitte’s federal and commercial health clients and a thought leader in clinical public health leadership and preparedness. He serves as a consultant to health industry and corporate boards, improving private sector and government care by strategically planning sustainable models of care. He has a MD and a MPH from the Harvard School of Public Health and is board certified in Aerospace Medicine.